Real-time SEC Filing Alerts & Continuous Market Intelligence

Automated monitoring and AI summaries for SEC, FDA, EPA, and government filings — delivered to your Inbox.

8:00 AM:
Before-Market
Digest {}
Real-time Alerts
{ ALERT }:$AAPL 10-K //
10:30 AM:
Morning Momentum
Digest //
12:30 PM:
Midday Pulse
Digest {}
Real-time Alerts
{ ALERT }:$XOM Form 4 }
1:15 PM:
Mid-Market
Digest {}
Real-time Alerts
{ ALERT }:$DAL 8-K }
Real-time Alerts
{ ALERT }:$PEP DEF 14A }
3:00 PM:
Power Hour
Digest {}
6:00 PM:
Evening Edge
Digest //
Real-time Alerts
{ ALERT }:$NVDA S-1 }
9:00 PM:
Daily Digest {}
8:00 AM:
Before-Market Digest {}
Real-time
$AAPL 10-K Alert //
10:30 AM:
Morning Momentum //
12:30 PM:
Midday Pulse Digest {}
1:15 PM:
Mid-Market Digest {}
3:00 PM:
Power Hour Digest {}
6:00 PM:
Evening Edge Digest //
9:00 PM:
Daily Digest {}
Continuous Advantage

The market never sleeps. Neither does our engine.

Stop waiting for end-of-day summaries. Catch catalysts as they happen with an uninterrupted flow of distilled market intelligence.

Gunpowder
Sent:9:00 PM ET{}

Daily USA Market Intelligence

March 10, 2026
Filings Analyzed
50from Mar 10
Executive Summary
50 filings analyzedMarch 10, 2026
Across 50 SEC filings for March 10, 2026, dominant themes include widespread equity dilution from ATM offerings, private placements, and shelf registrations (e.g., Trio Petroleum $17.4M sold/18.1M shares, Aclaris $39.8M/12.7M shares, AN2 $40M), signaling capital needs amid mixed FY25 results with average revenue growth of ~10% YoY in reporting companies (TWFG +22%, Arq +10%, Custom Truck +7.9%) but frequent net loss widening (Bullish -$785M vs +$80M, Arq -$52.6M vs -$5.1M, Trailblazer -$8.3M vs +$0.28M) driven by impairments and fair value hits. Healthcare firms reaffirmed FY26 guidance despite regulatory headwinds (Elevance $25.50+ EPS amid CMS sanctions effective March 31, Centene >$3.00 adj EPS), while SPAC/de-SPAC activity surged with amendments facilitating deals (IQM/RAAQ $1.8B value, Horizon Quantum PIPE $111.9M). Energy/mining showed operational challenges (URANIUM sales -59% YoY, Arq pausing GAC production) offset by balance sheet strengthening via raises, and REITs/RE faced revenue declines (Creative Media -6.3%, ACRES NII -19%). Capital allocation leaned toward buybacks (News Corp $1B program) and debt raises (Duke $1.3B notes), with M&A catalysts imminent (Alexander & Baldwin merger ~March 12). Portfolio-level trends highlight margin compression averaging -150bps in 6/10 industrials/energy (Arq -830bps gross), but improving EBITDA in select names (UNFI +23.4%, TWFG +47%). Implications favor monitoring biotech catalysts and SPAC closes for alpha, while dilution risks weigh on small caps.
Priority Breakdown: 50 filings analyzed — High: 23, Medium: 27, Low: 0
Key Events
8 events
Elevance Health/CMS Sanctions
Monitor resolution pre-March 31 effective date, FY26 guidance impact, prior 8-K March 2
◆
Arq/GAC Optimization
FY26 no GAC contribution, review outcome for EBITDA $17-20M guide, Q1 earnings for updates
◆
Lipocine/LPCN 1154
Phase 3 topline early April 2026, NDA mid-2026 potential, post-$24.7M cash raise
◆
+ 5 more events in full digest
Market Themes
6 themes
Biotech/Health Dilution Wave
8/12 biotech filings show equity raises (Aclaris $39.8M/12.7M sh, AN2 $40M, Lipocine ATM to $24.7M cash), avg +5-10% dilution but funds Phase 3 catalysts (LPCN 1154 Apr 2026), mixed sentiment implies near-term pressure but pipeline upside
●
SPAC/de-SPAC Momentum
6 filings with amendments/progress (IQM/RAAQ $1.8B/$175M trust, Horizon Quantum $111.9M PIPE reduction rights, Climate Transition $150M IPO), low redemptions key, Q2 2026 closes offer merger arb plays
●
Healthcare Guidance Resilience
4 majors reaffirm FY26 (Elevance $25.50 EPS despite sanctions Mar 31, Centene >$3.00, TransUnion confirms pre-Mexico acq), vs regs/CMS risks, sector avg benefit ratios stable
●
+ 3 more themes in full digest
Notable Developments
12 highlights
Pershing Square Capital Management(BULLISH)
S-1 for IPO highlights $2.1B Vantage Acquisition closing Q2 2026, core strategy of high-quality growth stakes, positive sentiment
▲
Elevance Health(BULLISH)
Reaffirmed FY26 adj EPS >=$25.50 and benefit ratio 90.2% +/-50bps despite CMS sanctions effective March 31, 2026, showing resilience
▲
Aclaris Therapeutics(BULLISH)
Sold 12.7M shares for $39.8M gross proceeds March 2-9 to institutional buyers like Deep Track Capital, bolstering cash without operational declines
▲
+ 9 more highlights in full digest
Compliance Alerts
10 alerts
Trio Petroleum(HIGH RISK)
$17.4M/18.1M shares sold via ATM since Jan 2026, only $1.6M left of $19M max, rapid fundraising implies heavy dilution
▼
Bullish(HIGH RISK)
FY25 net loss $785M vs +$80M in 2024 (digital assets fair value -$675M), sales -2% YoY to $244.8B, admin +19%
▼
U Power(HIGH RISK)
F-1 units at $1.31 with reset warrants to 50% exercise price, up to 21.1M extra shares, Nasdaq delist risk from $5M min value rule
▼
+ 7 more alerts in full digest
📂 View Complete Digest
View all 50 filings with complete AI analysis.
View Full Digest →

Live Market Intelligence. Delivered instantly.

We monitor global markets in real-time, synthesizing millions of unstructured data points into actionable signals before they hit the mainstream news cycle.

Live Intelligence Feed
Volatility: High
--:--
Connecting to Live Feed...Establishing secure connection to market intelligence streams
--:--
Awaiting SignalsMonitoring exchanges for new material disclosures
--:--
System ActiveEngine is processing unstructured data points
--:--
StandbyReady to synthesize the next alert
--:--
Connecting to Live Feed...Establishing secure connection to market intelligence streams
--:--
Awaiting SignalsMonitoring exchanges for new material disclosures
--:--
System ActiveEngine is processing unstructured data points
--:--
StandbyReady to synthesize the next alert
What lands in your inbox

This is a real alert. Not a notification — a briefing.

Every material SEC filing, distilled into a decision-ready brief — the company, the event, the AI analysis, the risks — in your inbox seconds after it hits the wire. Swipe through seven we actually sent.

GunpowderVisit Dashboard →

New SEC Filing Alert

June 08, 2026
Filing Details
VAIL RESORTS INC[MTN]
10-Q
June 08, 2026 at 12:00 AM ET
Accession: 0000812011-26-000026
HIGH PRIORITY
Event Intelligence
  • Event Types: Periodic Report, Financial Results
  • Category: Quarterly Results
AI Analysis

Sentiment: Mixed

Vail Resorts reported a decline in total net revenue for both the three and nine months ended April 30, 2026, compared to the same periods in 2025. Net income attributable to Vail Resorts decreased 19.3% to $314.4M for the quarter and 26.7% to $337.7M for the nine-month period. However, the company reduced total liabilities by $254.1M from July 2025 and improved stockholders' equity by $162.2M over the same period.

  • Lift revenue declined 5.3% to $729.4M for the quarter and 3.5% to $1.405B for the nine-month period.
  • Ski School revenue fell 11.5% to $141.8M for the quarter and 9.9% to $270.3M for the nine-month period.
  • Dining revenue decreased 10.7% to $99.1M for the quarter and 8.5% to $203.6M for the nine-month period.
  • Retail/Rental revenue declined 8.3% to $104.2M for the quarter and 6.2% to $261.0M for the nine-month period.
  • Owned hotel rooms revenue dropped 14.9% to $12.9M for the quarter and 4.5% to $54.0M for the nine-month period.
  • Managed condominium rooms revenue fell 13.1% to $28.3M for the quarter and 10.2% to $64.1M for the nine-month period.
  • Transportation revenue decreased 22.9% to $5.2M for the quarter and 17.2% to $11.4M for the nine-month period.
  • Interest expense increased 22.5% to $51.3M for the quarter and 19.4% to $152.1M for the nine-month period.
  • Provision for income taxes decreased 18.8% to $105.6M for the quarter and 25.6% to $117.3M for the nine-month period.
  • Cash and cash equivalents decreased 20.5% from $467.0M (April 30, 2025) to $371.4M (April 30, 2026).
  • Long-term debt due within one year decreased from $591.5M (April 30, 2025) to $73.5M (April 30, 2026), while long-term debt (net) increased from $2.119B to $2.950B over the same period.
  • Dividends declared per share remained flat at $2.22 per quarter and $6.66 for the nine-month period.
  • Weighted-average basic shares outstanding decreased 4.3% from 37,241 to 35,633 for the quarter.
SEC Summary: Filed: 2026-06-08 AccNo: 0000812011-26-000026 Size: 9 MB
View Full Filing

We monitor the exchanges and extract the key signals so you don't have to.

40+ daily digest streams extracted from exchanges and regulatory agencies—automatically summarized, organized, and delivered to your Email inbox, Slack, Telegram or Discord.

We monitor the exchanges and extract the key signals so you don't have to.

Advanced Daily Market Insights

Get concise AI-generated summaries highlighting market impact, sentiment, and key takeaways. Smart analysis sent daily at 9 PM. All AI analysed filings are accessible on the web app 24x7.

Advanced Daily Market Insights

Comprehensive filings monitoring. Covered.

Track investment signals, risks, red flags, insider activity, and notable developments from all exchanges and regulatory agencies from a single platform.

Comprehensive filings monitoring. Covered.

Smart Market Theme Analysis

Expert level market theme analysis for investors and traders. Get ahead of the market with our AI-powered key events highlights.

Smart Market Theme Analysis

SMART MONEY

Track what the best-informed money is doing.

Congressional disclosures, superinvestor 13F moves, and corporate insider activity — each scored, themed, and fused into one view. We surface the rare moments when all three lean the same way on the same stock.

The convergence signal

When a member of Congress buys, several superinvestor funds add, and corporate insiders buy the same stock inside 45 days — that is a convergence.

Illustrative — a hypothetical pattern, not a recommendation.

8 hours of reading.
8 minutes with Gunpowder.

SEC filings are long, dense, and time-consuming to read. Gunpowder's AI extracts key information in minutes, so your team can focus on analysis instead of document hunting.

Manual review: 8+ hours
Gunpowder: 5 minutes

From the Blog

// DAILY
{ United States }

Biotech Small-Cap Approvals — October 16, 2026

This digest covers a single-day-window stream of three FDA actions dated October 9 to 13, 2026, with no NMEs classified by mix (0 NME, 0 biosimilar, 0 label expansion in the mix tally) and three 'Other' designations; however, the individual analyses identify PRITELIVIR (AiCuris Anti-Infective Cures AG) as an NME approval under Priority Review, making it the highest-conviction event in the set. Pritelivir, branded HOVILPR, carries an 8/10 signal strength and materiality, and its Priority Review designation signals FDA recognition of significant unmet need in its indication. The remaining two actions are a biosimilar-designated approval of donepezil hydrochloride from Strides Pharma International (neutral, 5/10) and a label expansion for iopamidol (ISOVUE READI) from Bracco (bullish, 5/10). No dominant therapeutic area cluster is evident from the available data, as the three approvals span antiviral, neurology, and contrast imaging categories. The key watch item is the classification inconsistency: the Donepezil entry is labeled biosimilar in its summary yet the approval type is recorded as FALLBACK, and commercial metrics across all three entries are NOT_DISCLOSED, limiting quantitative conviction.

daily · October 16, 2026 · United States
// DAILY
[ United States ]

NME Blockbuster Approvals — October 16, 2026

This digest covers a single FDA approval event in the October 16, 2026 reporting window, which is the sole entry in the NME Blockbuster Approvals stream. The approval mix is 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other action, so no first-in-class molecular entity or biosimilar entrant is captured in this period. The one event is PRITELIVIR (HOVILPR), approved for AICURIS Anti-Infective Cures AG under a Priority Review designation, which the source classifies as an NME approval with a fallback approval-type tag. The highest-conviction signal is bullish (strength 8/10, materiality 8/10) for AICURIS, given that Priority Review status signals FDA recognition of significant benefit, though peak sales, exclusivity period, pricing power, and market position are all NOT_DISCLOSED and cannot be quantified from available data. No therapeutic area clustering is observable from a single approval. The key watch item is the classification ambiguity (NME label versus fallback approval type), which should be verified against the FDA action letter before the position is sized, along with the absence of any disclosed commercial parameters.

daily · October 16, 2026 · United States
// DAILY
{ United States }

Big Pharma Approvals — October 16, 2026

This digest covers a single FDA approval event for the period October 16, 2026, a label expansion for baricitinib (OLUMIANT) sponsored by Eli Lilly and Co. The approval mix is 0 NMEs, 0 biosimilars, 0 label expansions by the classification provided (the one approval is categorized as 'Other' with a FALLBACK approval type), so no new molecular entity or biosimilar signal is present this period. The single event carries a bullish signal (strength 5/10, materiality 5/10), reflecting incremental indication-driven revenue potential for an established oral JAK inhibitor rather than a new franchise. No therapeutic area clustering can be drawn from a single approval. The key watch item is that commercial parameters (peak sales, exclusivity, pricing power, market position) are not disclosed in the source data, so the magnitude of the expansion cannot be sized from this digest alone.

daily · October 16, 2026 · United States
// DAILY
[ United States ]

New Drug Approvals (Original) — October 16, 2026

This digest covers a single-day window (October 16, 2026) and three original approvals in the New Drug Approvals stream, but the approvals themselves are dated October 9 and October 13, 2026. The mix is 0 NMEs, 0 biosimilars, 0 label expansions, and 3 other, so the classification data does not produce a conventional NME/biosimilar/expansion breakdown. Of the three, PRITELIVIX-equivalent signal aside, the highest-conviction item is PRITELIVIR (HOVILPR) from AiCuris Anti-Infective Cures AG, which the source data describes as an NME approval under Priority Review with a bullish signal at strength 8/10. IOPAMIDOL (ISOVUE READI) from Bracco received a bullish label expansion signal at 5/10, while DONEPEZIL HYDROCHLORIDE from Strides Pharma International carries a neutral signal at 5/10 despite being described as a biosimilar approval, an internal inconsistency that should be verified. No dominant therapeutic area cluster is identifiable from a set this small, and commercial metrics (peak sales, exclusivity, pricing power, market position) are NOT_DISCLOSED across all three approvals. The key watch item is the approval-type classification conflict for DONEPEZIL, which, if it is in fact a biosimilar, would carry originator-side erosion implications for Eisai's Aricept franchise; that linkage is inferred rather than sourced here.

daily · October 16, 2026 · United States
// DAILY
{ United States }

Federal Construction & Infrastructure Contracts — October 16, 2026

This digest covers a single federal construction award totaling $35,935,733 in obligation, made by the Department of Veterans Affairs (civilian, zero defense-related awards) to CARIBE TECNO CRL for Phase 5 parking garage construction at VAMC San Juan. The base-plus-options value is $63,001,943, so obligation represents roughly 57% of ceiling, and $13,861,385 (about 39% of obligated value) had been outlaid as of the data date. The dominant theme is civilian VA facilities construction under a total small business set-aside, a policy-driven award rather than a competitive win. The highest-conviction read is that the award is operationally visible but not investable, since the recipient is privately held with no ticker or financial disclosures. The key watch item is the 2026-10-14 contract end date, which falls just before this digest's period and makes option exercise, schedule adherence, and outlay progress the critical near-term monitoring points.

daily · October 16, 2026 · United States
// DAILY
[ United States ]

DOD Defense Contracts Intelligence — October 16, 2026

This digest covers a single DOD-stream contract record totaling $32,680,359 in obligations, with 0 of 1 records classified as defense-related under the stream's criteria despite the Department of the Army as awarding agency. The dominant theme is Army Corps of Engineers (ENDIST Kansas City) funding for Superfund remediation, specifically the WACC Superfund OU1 Remedial Action at Ridgewood, NY, awarded to Sevenson Environmental Services, Inc. on 2024-06-18. The highest-conviction read is structural rather than directional: the Cost Plus Fixed Fee pricing shifts most cost-overrun risk to the government, which lowers contractor downside, though the fixed fee caps profit upside. The key watch item is that no outlays had been reported ($0 disbursed), and the data does not establish whether Sevenson is publicly traded, so investment relevance cannot be confirmed from this record alone. Average signal strength is 4.0/10 with a materiality score of 3/10, so this single record is low-materiality for portfolio decisions.

daily · October 16, 2026 · United States
// DAILY
{ United States }

DHS Homeland Security Contracts — October 16, 2026

Three DHS awards totaling $68,681,923 in obligations were analyzed for the October 16, 2026 period, with zero defense-related records and all three classified as civilian homeland security work. The largest award, GOLDEN SVCS, LLC's $35,454,081 Armed Guard II delivery order from DHS Federal Protective Service (2024-09-01 to 2027-08-31), carries the highest materiality but its public-company exposure cannot be confirmed from the data. LMD AGENCY, INC.'s $20,000,000 CBP national media campaign BPA call (awarded 2026-09-20) has $0 outlayed to date, so its revenue pace is unproven. LEIDOS, INC.'s $13,227,842 TSA delivery order is a closed-out 2017 award with only $57 outlayed, offering little current signal. The highest-conviction takeaway is that the DHS physical-security stream is durable but low-materiality for listed investors; the primary watch item is whether obligations from the GOLDEN and LMD awards convert into actual outlays, given that $13.2M of GOLDEN's ceiling remains unobligated and LMD has recorded no outlays.

daily · October 16, 2026 · United States
// DAILY
[ United States ]

VA Healthcare & Services Contracts — October 16, 2026

Three VA construction and healthcare-facility awards totaling $68,397,022 were analyzed, with 0 of 3 defense-related, so the entire digest falls under the civilian (Department of Veterans Affairs) context. The dominant theme is VA facility construction under set-asides: CARIBE TECNO CRL's $35,935,733 parking garage at VAMC San Juan (the largest obligation, 52.5% of the aggregate), TROOP CONTRACTING INC's $17,407,128 sterile processing expansion at the Captain James A. Lovell FHCC, and SENATE BUILDERS & CONSTRUCTION MANAGERS, INC.'s $15,054,159 administration building at the Wilmington VA Medical Center. All three are rated neutral with strength 3/10 and materiality 2/10, and none of the recipients is identified as publicly traded, so direct equity exposure cannot be established from this data. The highest-conviction signal is the steady flow of VA facility construction spending reaching SDVOSB and small-business contractors, though this is a demand indicator rather than a tradable thesis. The key watch item is outlay progression: CARIBE TECNO's $13,861,385 outlayed against its 2026-10-14 end date and the $0 outlayed on the two later-stage awards will determine whether these projects are executing on schedule.

daily · October 16, 2026 · United States
// DAILY
{ United States }

New Federal Contractors — October 16, 2026

The 27 new federal contract awards in this period total $602,147,093 in obligations, with only one defense-related award (the GSA-routed Sigma Defense Systems LLC Joint AISR integration and sustainment order at $23,872,699) and the remaining 26 split across civilian agencies including HHS, VA, DHS, Treasury, USDA, NASA, and GSA. No single award is individually material to a large public parent based on the data provided, and every record is rated neutral, so the investment signal is one of breadth rather than concentration. The most meaningful individual awards are the Whitestone Group HHS security guard order ($51,818,963), the Caribe Tecno VA parking garage construction ($35,935,733), and the GOLDEN SVCS DHS Armed Guard II order ($35,454,081), but none of the recipients is shown to be publicly traded, so direct equity exposure cannot be confirmed. The dominant theme is recurring civilian services and IT labor work, with little evidence of new defense growth in this window. The main watch item is that most records lack outlay progress or recipient ownership data, so materiality and investability cannot be verified for the majority of awards.

daily · October 16, 2026 · United States
// DAILY
[ United States ]

Significant Contract Modifications ($10M+) — October 16, 2026

The 27 significant contract modifications in this period total $602,147,093 in obligations, with only one defense-related award (Sigma Defense Systems LLC, $23,872,699 via GSA on behalf of ACC) and the remainder civilian, led by HHS, DHS, VA, GSA, and NASA. The dominant theme is labor-based civilian services and IT support (security guards, application development, data analytics, engineering support) rather than defense platform spending. Most individual awards are small relative to public-company revenue bases, and most recipients are private, nonprofit, or lack disclosed parent listings, so direct investability is limited across the set. The highest-materiality items are Whitestone Group ($51.8M, HHS security services), StoneX Financial ($32.7M, U.S. Mint silver delivery with $0 outlayed and an 8-day performance window), and Sevenson Environmental Services ($32.7M, Army Superfund remediation), though none establish a clear public-equity catalyst. The key watch item is the large share of obligations with $0 or unexplained outlays (including a negative $-1,352 outlay on the USPTO HALVIK award), which limits confidence in realized revenue until billing data confirms execution.

daily · October 16, 2026 · United States
// DAILY
{ United States }

Contract Deobligations Alert — October 16, 2026

The 27 contracts in this deobligations-alert stream total $602,147,093 in obligations, with only one defense-related award (Sigma Defense Systems LLC, $23,872,699 via GSA on behalf of defense customers) and the remainder civilian, led by DHS, HHS, VA, GSA, and NASA. No contract in the set carries a clear bullish or bearish signal; all 27 are rated neutral at an average strength of 3.0/10, reflecting that most recipients are private or nonprofit entities with no disclosed public parent. The highest-materiality items are Whitestone Group ($51.8M, HHS security guard services, roughly 90% outlayed), Caribe Tecno ($35.9M VA parking structure), and GOLDEN SVCS ($35.5M DHS Armed Guard II), though none is linked to an identifiable investable equity. The clearest watch items are contracts with stalled or unexplained outlay data, notably Steampunk and Leidos closeout anomalies, HALVIK's negative $-1,352 outlay, and Deloitte's $0 outlay on a $30.5M delivery order, plus several awards whose current end dates have already passed (ECS Federal, Booz Allen, Leidos, Data Computer Corp).

daily · October 16, 2026 · United States
// DAILY
[ United States ]

Contract Option Exercises — October 16, 2026

The 27 option-exercise and delivery-order records in this period total $602,147,093 in obligations, with only 1 defense-related award (GSA-routed Sigma Defense Systems LLC, $23,872,699) and the remainder civilian, led by HHS, DHS, VA, USDA, NASA and GSA. Every record was classified neutral (average signal strength 3.0/10), so the batch offers no directional bullish or bearish call; its value lies in the contract-level execution and visibility detail. The largest awards, The Whitestone Group ($51,818,963, HHS security guard services) and Caribe Tecno CRL ($35,935,733, VA parking garage), are service or construction work with no stated public-market parent, limiting investability. The most useful execution signal is the high outlay ratio on Booz Allen-era and Steampunk-type IT work, while the main watch item is the large share of records showing $0 or near-zero outlays (StoneX, Sevenson, Sigma, LMD, Senate Builders), which leaves realized revenue unverified and makes near-term earnings contribution uncertain.

daily · October 16, 2026 · United States

FAQ

Frequently asked questions

Gunpowder monitors all major SEC filing types including 10-K (annual reports), 10-Q (quarterly reports), 8-K (current reports), DEF 14A (proxy statements), 13-F (institutional holdings), and many more. Configure your alerts to focus on the filing types relevant to your research or compliance needs.

New filings are processed within minutes of being published to agency databases. AI summaries typically complete within 2-5 minutes, depending on document length. You will receive alerts shortly after processing is complete.

Yes! Beyond SEC filings, Gunpowder also monitors filings from the FDA, FCC, EPA, and other regulatory agencies. This gives you a comprehensive view of regulatory activity in one place.

Our AI reads through entire filings and extracts key information, including risk factors, notable disclosures, and important changes. The summaries are designed to give you the key takeaways in under 60 seconds.

Gunpowder integrates with Slack, Discord, email, and webhooks for alerts. We also offer API access for custom integrations with your existing workflow, CRM, or internal tools.

Yes, we offer a 14-day free trial with full access to all features. No credit card required. You can set up alerts for multiple companies and agencies during your trial period.